NCT03111108View on ClinicalTrials.gov

Efficacy and Safety of Elbasvir (MK-8742) + Grazoprevir (MK-5172) in Treatment-Naïve/Treatment-Experienced (TN/TE) French Participants With Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection (MK-5172-096)

PHASE4CompletedINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

June 20, 2017

Primary Completion Date

October 15, 2018

Study Completion Date

October 15, 2018

Conditions
Hepatitis C Virus (HCV) Infection
Interventions
DRUG

EBR/GZR (50 mg/100 mg) FDC

One FDC tablet taken once daily by mouth for 8 or 12 weeks depending upon randomization.

Trial Locations (13)

Unknown

CHU Amiens-Picardie - Hopital Sud ( Site 0217), Amiens

CHU Jean Minjoz ( Site 0213), Besançon

CHU Henri Mondor ( Site 0206), Créteil

CHU de Grenoble - Hopital Michallon ( Site 0208), Genoble

CHU Dupuytren ( Site 0209), Limoges

Hopital Saint Eloi ( Site 0207), Montpellier

C.H.U. de Nice Hopital de l Archet 2 ( Site 0215), Nice

Centre Hospitalier Regional du Orleans ( Site 0212), Orléans

Hopital Beaujon ( Site 0201), Paris

Hopital Cochin ( Site 0211), Paris

Hopital Saint Antoine ( Site 0200), Paris

CHU de Toulouse - Hopital Purpan ( Site 0216), Toulouse

CHU de Nancy Hopital Brabois Adultes ( Site 0204), Vandœuvre-lès-Nancy

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT03111108 - Efficacy and Safety of Elbasvir (MK-8742) + Grazoprevir (MK-5172) in Treatment-Naïve/Treatment-Experienced (TN/TE) French Participants With Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection (MK-5172-096) | Biotech Hunter | Biotech Hunter